Welcome to our dedicated page for TEVA PHARMACEUTICAL INDUSTRIES SEC filings (Ticker: TEVJF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TEVA PHARMACEUTICAL INDUSTRIES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TEVA PHARMACEUTICAL INDUSTRIES's regulatory disclosures and financial reporting.
Teva Pharmaceutical Industries Ltd. (TEVA) announced multiple new senior note issuances totaling €1.5 billion and $3.2 billion through its subsidiaries Teva Finance II, III and IV on September 16, 2026. The euro tranches are €1,000,000,000 of 4.250% Senior Notes due 2033 and €500,000,000 of 4.625% Senior Notes due 2036, and the U.S. dollar tranches are $1,200,000,000 of 5.250% Senior Notes due 2032, $1,000,000,000 of 5.500% Senior Notes due 2034 and $1,000,000,000 of 5.750% Senior Notes due 2037.
Teva intends to use net proceeds primarily to fund conditional redemptions of several higher‑coupon existing notes, including 6.750% Senior Notes due 2028 and multiple sustainability‑linked notes, and for general corporate purposes. The new notes are senior unsecured obligations, fully and unconditionally guaranteed on a senior unsecured basis by Teva, with standard covenants, change‑of‑control repurchase rights at 101% of principal, and make‑whole and par call redemption provisions by series.
Teva Pharmaceutical Industries Ltd. (TEVA) reports that on September 14, 2026 its ordinary shares began trading on the New York Stock Exchange under the ticker “TEVA,” replacing its American depositary shares (ADSs). On the same date, Teva’s ADS program terminated, with each ADS exchanged for one ordinary share.
The company’s ordinary shares continue to trade on the Tel Aviv Stock Exchange under the symbol “TEVA.” Additional details are available via the investor relations section of Teva’s website.
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) is having its American Depositary Shares, each representing one ordinary share, removed from listing and registration on the New York Stock Exchange LLC under Section 12(b) of the Securities Exchange Act of 1934. The New York Stock Exchange filed a Form 25, certifying it has complied with its own rules to strike this class of securities from listing under 17 CFR 240.12d2-2(b). The company is stated to have complied with the Exchange’s rules and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of this class of securities from listing and registration.
Teva Pharmaceutical Industries Ltd. (TEVA) announced that its Dutch financing subsidiaries priced a multi‑tranche offering of approximately $4.9 billion (equivalent) in senior notes, guaranteed on a senior unsecured basis by Teva. The new Securities comprise €1,000,000,000 of 4.250% notes due 2033, €500,000,000 of 4.625% notes due 2036, $1,000,000,000 of 5.500% notes due 2034, $1,000,000,000 of 5.750% notes due 2037, and $1,200,000,000 of 5.250% notes due 2032, each priced slightly below par. Settlement is expected on or about September 16, 2026, subject to customary closing conditions.
Teva expects to use the net proceeds, together with cash on hand, to fund conditional redemptions of several higher‑coupon outstanding series, including all 6.750% Senior Notes due 2028, all 7.875% and 7.375% Sustainability‑Linked Senior Notes due 2029, up to $450,000,000 of 4.750% Sustainability‑Linked Notes due 2027, and up to €1,150,000,000 of 4.375% Sustainability‑Linked Notes due 2030, as well as to pay related fees and, to the extent of any remaining proceeds, for general corporate purposes, including repayment of other debt.
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) is issuing new senior unsecured Euro- and U.S. dollar‑denominated notes through three Dutch finance subsidiaries, with all principal and interest unconditionally guaranteed by Teva. The notes have maturities in 2032, 2033, 2034, 2036 and 2037 and pay annual interest in euros and semi‑annual interest in U.S. dollars.
Teva expects to use the net proceeds, together with cash on hand, primarily to fund conditional redemptions of existing higher‑coupon debt, including all outstanding 6.750% Senior Notes due 2028, all 7.875% and 7.375% sustainability‑linked Senior Notes due 2029, up to $450 million of 4.750% sustainability‑linked Senior Notes due 2027 and up to €1.25 billion of 4.375% sustainability‑linked Senior Notes due 2030, plus related fees and expenses, with any remainder used for general corporate purposes and further debt repayment.
Teva reports 2025 net revenues of $17.26 billion, GAAP net income attributable to Teva of $1.41 billion and Adjusted EBITDA of $5.31 billion, with total assets of $40.75 billion and total equity of $7.91 billion as of December 31, 2025. As of June 30, 2026, cash and cash equivalents were $3.66 billion and total short‑term debt was $4.50 billion.
Teva Pharmaceutical Industries Limited (TEVA) reports a change in how it presents its operating segments and has retrospectively recast prior disclosures from its Form 10‑K for the year ended December 31, 2025. Effective January 1, 2026, Anda, Teva’s U.S. distribution business, is no longer part of the United States segment and is reported within Other Activities.
The recast updates segment information in Business, Management’s Discussion and Analysis, and Financial Statements and Supplementary Data to align with Teva’s Pivot to Growth strategy and internal reporting. Teva states that consolidated balance sheets, income statements, cash flows and other disclosures from the original 2025 Form 10‑K are unchanged, and no new events after that report are reflected.
Teva Pharmaceutical Industries Ltd. (TEVA) reported a material modification to the rights of its security holders by amending its deposit agreement and updating the form of American depositary receipt in connection with terminating its American depositary share (ADS) program. Each ADS represents one ordinary share, par value NIS 0.10 per share.
The amendment establishes a mandatory exchange under which each ADS will be exchanged for one ordinary share, and all outstanding ADSs will be cancelled in exchange for an equal number of economically equivalent ordinary shares listed on the New York Stock Exchange. The termination of the ADS program is expected to occur at the open of business (New York time) on September 14, 2026.
TEVA (TEVA PHARMACEUTICAL INDUSTRIES LTD) reported insider transactions by Chief Accounting Officer Amir Weiss on 2026-08-21. Weiss exercised stock options covering 2,500 Ordinary Shares at an exercise price of $19.16 per share and then sold a total of 9,445 Ordinary Shares in open-market transactions, including 6,945 shares at a weighted average price of $37.61 (in a range of $31.62 to $37.61) and 2,500 shares at $37.63 per share. The options, which expire on March 2, 2028, were originally granted in 2018 and vested in tranches from 2019 to 2022. The Ordinary Shares may be represented by American Depositary Shares, each currently representing one Ordinary Share.
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) director Ronit Satchi-Fainaro reported selling 415 Ordinary Shares on August 21, 2026 at a price of $37.25 per share in an open-market or private transaction. Following this sale, the director directly holds 111,986 Ordinary Shares, which may be represented by American Depositary Shares, each currently representing one Ordinary Share.
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) reported that executive Evan Lippman, EVP, Business Development, sold 18,600 Ordinary Shares on August 17, 2026. The shares, which may be represented by American Depositary Shares on a one-for-one basis, were sold at a weighted average price of $36.5748, with individual trades between $36.57 and $36.61. After this sale, Lippman directly holds 25,591 Ordinary Shares. The transaction was effected under a Rule 10b5-1 trading plan adopted on May 16, 2026, indicating it followed a pre-established trading schedule.